Ask AI
ProCE Banner Activity

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Surgeon Perspective

Slideset

Download this slideset to review key data on the use of neoadjuvant immune checkpoint inhibitor–based therapy in resectable early-stage NSCLC from a surgeon’s perspective.

Released: December 01, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Jonathan Spicer, MD, PhD, FRCS

Professor, Division of Thoracic Surgery
Director, McGill Thoracic Oncology Network
McGill University, Montreal General Hospital
Montreal, Quebec

Jonathan Spicer, MD, PhD, FRCS: consultant/advisor/speaker: AstraZeneca, BMS, Johnson & Johnson, Merck; owner: NETosys Inc.; educational grants: Amgen, Boehringer Ingelheim, Pfizer, Regeneron.